▲ AI PRISM* Personalized Economic Briefing
* Editor’s note: AI PRISM (Personalized Report & Insight Summarizing Media) is an artificial intelligence-based personalized news recommendation and summary service developed with support from the Korea Press Foundation. It selects and provides six news items tailored to each reader type.
■ Samsung Group opens fall recruitment: Samsung Group has begun its second-half hiring process, recruiting about 6,000 new employees across 19 affiliates. Applications are accepted from the 8th through the 15th on the group’s recruitment website, Samsung Careers, and the company plans to concentrate its selection on talent in advanced technology fields including AI, semiconductors and bio.
■ Foreign chip firms move to recruit Korean talent with aggressive packages: Global semiconductor companies including Lam Research, ASML and Tokyo Electron are accelerating competition for top domestic talent with compensation packages reaching as high as 100 million won for new hires. Career paths into the chip industry, long centered on Samsung Electronics and SK hynix, are rapidly widening toward foreign firms.
■ GPT-6 Astra shock signals upheaval in the job landscape: OpenAI’s new model, GPT-6 Astra, demonstrated the ability to complete a 3D game within 45 minutes from just a few prompts, prompting assessments that the era of mainstream AI agents has begun in earnest. Some observers project that the job landscape centered on routine office work could be structurally dismantled as early as three years from now, requiring job seekers to reconsider their career selection strategies.
[News of Interest to University Job Seekers]
1. Samsung to Hire 6,000 New Employees at 19 Affiliates, Seeking Integrated Talent in Chips and AI
Key points: Samsung Group launched its second-half recruitment drive on the 8th, seeking about 6,000 new employees across 19 affiliates. Combined with first-half hiring, total recruitment this year comes to roughly 12,000 people, and demand for technical talent continues to expand as the group invests 110 trillion won in facilities and research and development. Screening methods differ by job family, with software applicants taking a software competency test instead of the GSAT and design applicants assessed through portfolio review. Samsung has announced plans to hire a total of 60,000 people over the five years through 2030, and analysts say this opens medium- to long-term opportunities for job seekers in AI, semiconductors and bio.
2. From 100 Million Won Salaries to Company Shares: Foreign Chip Firms Compete for Korean Talent
Key points: Global semiconductor companies including Lam Research, Micron, Tokyo Electron (TEL) and ASML are moving aggressively to attract core domestic talent with exceptional compensation. First-year compensation for new hires at TEL Korea ranges from 80 million to 100 million won, while starting pay at ASML Korea is about 70 million won, exceeding 100 million won from the second year once performance bonuses are added. Micron offers global career paths as well, including assignments at its large-scale semiconductor plants in the United States for new engineers. SEMI projects a shortage of 127,000 semiconductor specialists in Korea alone by 2030, suggesting that graduates in related fields will continue to gain bargaining power in the job market.
3. A Few Prompts, a 3D Game in 45 Minutes: “The Astra Moment Is Coming”
Key points: With the unveiling of OpenAI’s GPT-6 Astra, concerns about the structural dismantling of routine office work have moved into mainstream discussion. Astra recorded a perfect score across every subject on the 2026 college entrance exam and finished a Pokemon game in 18 hours and 12 minutes, displaying general reasoning ability that surpasses humans. Functions that experts had implemented only through complex multi-agent systems are now available through a standard $20 monthly subscription, effectively removing the barriers to entry for AI agents. Some observers also project that demand for hardware-related jobs will instead surge, driven by expanding need for HBM and semiconductor infrastructure as AI inference volumes climb.
[Reference News for University Job Seekers]
4. Musinsa, a 10 Trillion Won Decacorn, Files for KOSPI Listing Review
Key points: Musinsa, Korea’s largest fashion platform, has filed for preliminary listing review on the KOSPI with a target valuation of 10 trillion won, formally launching its initial public offering. Consolidated revenue reached 821.7 billion won in the first half of this year, up 22.5% from a year earlier, while transaction volume at its global stores serving 13 countries including Japan, the United States and Thailand surged 143% in the first quarter alone. In China, the company is expanding offline stores in partnership with Anta Sports, targeting 100 stores by 2030. A successful listing is expected to drive a significant expansion in hiring across the global fashion and commerce platform sector.
Key points: The government has begun formulating a long-term national strategy for science-based policing to counter new forms of AI-driven crime. The move follows a sharp rise in the abuse of AI, with deepfake crime cases surging from 168 in 2023 to 1,300 last year. The Presidential Advisory Council on Science and Technology plans to establish a full-cycle response system spanning prevention, investigation and victim protection, and to complete the national science-based policing strategy in the first half of next year. Demand for new job categories in AI security and cyber investigation is expected to grow, and analysts say new career paths will open for graduates in science, engineering and law.
6. Celltrion Takes Aim at Keytruda With FDA Approval for Phase 3 Biosimilar Trial
Key points: Celltrion disclosed that the U.S. Food and Drug Administration has approved a change to the Phase 3 clinical trial plan for CT-P51, a biosimilar candidate to the global blockbuster immuno-oncology drug Keytruda. The trial will run for two years in 220 patients with metastatic non-squamous non-small cell lung cancer, while CT-P44, a biosimilar to Darzalex, is entering Phase 3 trials in Korea. Both candidates remain at the Phase 3 stage, however, and the approval does not mean marketing authorization or clinical success. As competition in biosimilar development intensifies, hiring demand is expected to rise gradually for specialists in clinical trials and regulatory affairs as well as in bio regulatory science.
